5-Bromotryptophol, 97.0%, 10g

2-((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)acetic acid, 98%, 10g

(Methylsulfamoyl)amine, 97%, 5g

4-(4-tert-Butylphenyl)benzoic Acid>98.0%(GC)(T)5g

cis-4-(Hydroxymethyl)cyclohexanecarboxylic Acid>98.0%(GC)25g

6-bromo-7-fluoro-2,3-dihydrobenzo[b][1,4]dioxine, 96%, 1g

Methyl 3-bromo-2-methylbenzoate, 98.0%, 1g

2-Bromo-7-iodo-9H-fluorene, 95.0%, 5g

1-[6-(Trifluoromethyl)pyridin-2-yl]piperidine-4-carboxylic acid, 97.0%, 25g

4-Bromo-5-fluoro-2-methoxybenzoic acid, 97%, 250mg

(3aR,6aR)-tert-Butyl hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate, 98.0%, 1g

tert-Butyl 4-(4-aminophenylsulfonamido)piperidine-1-carboxylate, 95.0%, 1g

2-nitrobenzaldeide, minimo 98%, per sintesi, 250 g, confezione in plastica.